![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0006.png)
allied
academies
Page 24
Notes:
July 05-06, 2019 | Paris, France
Pharmaceutics and Advanced Drug Delivery Systems
2
nd
International Conference and Exhibition on
Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN:2249-622X | Volume 9
Detecting and profiling extracellular miRNAs among some Wilms Tumor Moroccan
patients using molecular biology tools
Sara Benlhachemi
1,2
, Mohammed Khattab
3,
Oumaima Ait Si Mohammed
1,2
and
El Mostafa El Fahime
1,2
1
National Center of Scientific and Technical Research, Morocco
2
Mohammed 5
th
University, Morocco
3
Hematology and Oncology Service of children’s Hospital, Morocco
N
ephroblastoma or Wilms Tumor (WT) results from the
abnormal kidney development at embryonic stage. WT
is the most common childhood renal malignancy (95 %) that
affects approximately 1/10000 children. Its current diagnosis
approach (medical imaging and pathological exam) takes
a long time before defining the appropriate treatment that
is generally presented in chemotherapy, surgery and X-Ray
treatment, which have harmful side effects on children’s
health.
The genetic and epigenetic factors associated with Wilms
tumor are the WT Suppressor tumor genes that have
an important role in normal kidney development. In the
case of nephroblastoma, overexpression of oncomirs
(Oncogenic miRNAs) inhibits their expression. MiRNAs are
small non-coding RNA sequences of 22nt that regulate
post-transcriptional gene expression. Moreover, miRNAs
originating from WT are overexpressed, so that we can find
them at high levels in blood circulation comparing with
other miRNAs. My research interest is to detect and profile
extracellularmiARNsamongsomeMoroccanWTpatients.This
has many goals; to use those miARNs as disease biomarkers
for diagnosis and prognosis of WT, to understand disease
pathogenesis and to correlate miRNA expression patterns
with disease progression. MiARNs could even have a role in
Cancer therapy by the injection of other miRNAs that inhibit
oncomirs. To achieve those goals, manymolecular techniques
are used from DNA and RNA extraction to DNA sequencing.
So far, we’ve succeeded in extracting miRNAs from different
materials as blood, serum, plasma and embedded paraffin
tissue. As well as transforming (reverse transcripting) those
miRNAs into cDNA for qRT-PCR and sequencing.
Speaker Biography
Sara Benlhachemi is a PhD student at Medical school, Mohammed
5
th
University, Morocco working on Cancer Epigenetics. Her thesis
is about detecting and profiling extracellular miRNAs among some
Wilms Tumor Moroccan patients using molecular biology tools.
She’s under the supervision of Professor EL Mostafa El Fahime at the
National Center of Scientific and Technical Research. She had her
Master’s Degree in Medical Biotechnology in 2016 at Medical school
of Rabat. Likewise, her end of study project was under the supervision
of Professor EL Mostafa EL Fahime and it was titled: “Approach for
highlighting mutations in ENPP1 gene among Moroccan patients with
Pseudoxanthoma Elasticum”. She had her Bachelor's Degree in 2014 at
Faculty of Sciences and Techniques – Mohammedia, her end of study
project was about the assessment of the early screening and diagnosis
of HIV infection in Morocco following the introduction of the quick
blood test, under the supervision of Dr Elmir ELHARTI at the National
HIV Reference Laboratory of the National Institute of Hygiene –Rabat.
e:
benlhachemi.sara@gmail.comSara Benlhachemi et al.
, Asian J Biomed Pharmaceut Sci, | ISSN: 2249-622X
Volume 9